The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: Half a century of anxiolytic drugs
Open accessThe DOI matches its Crossref record.
Abstract
The clinical introduction of chlordiazepoxide half a century ago was one of the major breakthroughs in the history of psychopharmacology, as it opened the door for the benzodiazepine saga, the pharmacological family par excellence in the treatment of anxiety disorders. This review analyses the discovery of this drug, which was filled with chance events, and numerous chemical and clinical errors of approach. Chlordiazepoxide, initially called methaminodiazepoxide, was patented in 1958 and introduced in clinical treatment in 1960 under the brand name Librium®. The benzodiazepines became the most widely prescribed drugs worldwide, provided truly effective treatment for "minor forms" (neuroses) of mental disorders for the first time, increased the quality of scientific methodology in clinical research, and enabled the development of new etiopathogenic theories for anxiety disorders, especially after the discovery in 1977 of their high-affinity receptor complex.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
Kurko, T. A. T., Saastamoinen, L. K., Tähkäpää, S., Tuulio-Henriksson, A., Taiminen, T., Tiihonen, J., Airaksinen, M. S., & Hietala, J. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.09.003 · Cited by 280
Anxiety-like behavior in crayfish is controlled by serotonin
Fossat, P., Bacqué-Cazenave, J., De Deurwaerdère, P., Delbecque, J.-P., & Cattaert, D. (2014) · Science · doi:10.1126/science.1248811 · Cited by 275
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
The discovery of suvorexant, the first orexin receptor drug for insomnia
Coleman, P. J., Gotter, A. L., Herring, W. J., Winrow, C. J., & Renger, J. J. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104837 · Cited by 128
Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
Screening of Benzodiazepines in Thirty European Rivers
Fick, J., Brodin, T., Heynen, M., Klaminder, J., Jonsson, M., Grabicova, K., Randak, T., Grabic, R., Kodes, V., Slobodnik, J., et al. (2017) · Chemosphere · doi:10.1016/j.chemosphere.2017.02.126 · Cited by 76
Torres-Bondia, F., de Batlle, J., Galván, L., Buti, M., Barbé, F., & Piñol-Ripoll, G. (2020) · BMC Public Health · doi:10.1186/s12889-020-08984-z · Cited by 69
Clinical Methodology Matters in Epidemiology: Not All Benzodiazepines Are the Same
Cosci, F., Guidi, J., Balon, R., & Fava, G. A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000437201 · Cited by 27
Aumento da utilização de benzodiazepínicos entre idosos mais velhos: Projeto Bambuí
Oliveira, A. L. M. L., Nascimento, M. M. G. D., Castro-Costa, É., Firmo, J. O. A., Lima-Costa, M. F., & Loyola Filho, A. I. D. (2020) · Revista Brasileira de Epidemiologia · doi:10.1590/1980-549720200029 · Cited by 17
Long-term neurological consequences following benzodiazepine exposure: A scoping review
Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R. (2025) · PLOS One · doi:10.1371/journal.pone.0330277 · Cited by 7
“In 1960, the first benzodiazepine, chlordiazepoxide (Librium), was released to market and became the most-prescribed drug in the United States until it was eclipsed by another benzodiazepine, diazepam (Valium) [2].”
Metadata
- Authors
- López-Muñoz, F., Álamo, C., & García-García, P.
- Venue
- Journal of Anxiety Disorders
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 25
- Issue
- 4
- Pages
- 554-562
- ISSN
- 0887-6185 (ISSN-L)
- OpenAlex
- W2070105490
- Cited by
- 144
- References
- 0
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.